Not 'TIL' 2024: Iovance’s lifileucel faces yet another approval delay, this time due to FDA resource constraints
Iovance Biotherapeutics’ bid for approval of its melanoma therapy has been hit with its fourth year of delay, as FDA resource constraints forced the agency …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
